Eicosanoids in Nonalcoholic Fatty Liver Disease (NAFLD) Progression. Do Serum Eicosanoids Profile Correspond with Liver Eicosanoids Content during NAFLD Development and Progression?
Animals
Biomarkers
/ analysis
Chromatography, Liquid
Dinoprostone
/ analysis
Disease Models, Animal
Disease Progression
Docosahexaenoic Acids
/ analysis
Eicosanoids
/ blood
Eicosapentaenoic Acid
/ analogs & derivatives
Hydroxyeicosatetraenoic Acids
/ analysis
Linoleic Acids
/ analysis
Lipoxins
/ analysis
Liver
/ metabolism
Male
Non-alcoholic Fatty Liver Disease
/ blood
Rats
Rats, Sprague-Dawley
13-HODE
9-HODE
NAFLD
NASH
biomarkers
eicosanoids
Journal
Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009
Informations de publication
Date de publication:
27 Apr 2020
27 Apr 2020
Historique:
received:
25
03
2020
revised:
22
04
2020
accepted:
23
04
2020
entrez:
1
5
2020
pubmed:
1
5
2020
medline:
9
2
2021
Statut:
epublish
Résumé
Nonalcoholic fatty liver disease (NAFLD) is becoming a major public health problem worldwide. The study aimed to evaluate the concentration of eicosanoids in serum and liver tissue during steatosis progression and to assess whether eicosanoid change scores may predict liver tissue remodeling. Thirty six eight-week-old male Sprague Dawley rats were enrolled and sacrificed at different stages of NAFLD. Eicosanoid concentrations, namely lipoxin A
Identifiants
pubmed: 32349225
pii: molecules25092026
doi: 10.3390/molecules25092026
pmc: PMC7248881
pii:
doi:
Substances chimiques
10,17-dihydroxydocosa-4,7,11,13,15,19-hexaenoic acid
0
7,14-dihydroxydocosa-4,8,10,12,16,19-hexaenoic acid
0
Biomarkers
0
Eicosanoids
0
Hydroxyeicosatetraenoic Acids
0
Linoleic Acids
0
Lipoxins
0
lipoxin A4
0
resolvin D1
0
Docosahexaenoic Acids
25167-62-8
13-hydroxy-9,11-octadecadienoic acid
5204-88-6
Eicosapentaenoic Acid
AAN7QOV9EA
5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoic acid
GND3JH08JA
Dinoprostone
K7Q1JQR04M
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Narodowe Centrum Nauki
ID : 2016/21/N/NZ5/02584
Références
Int Immunol. 2019 Aug 23;31(9):559-567
pubmed: 30772915
Hepatology. 2005 Jun;41(6):1313-21
pubmed: 15915461
Mol Cancer. 2003 Jan 07;2:10
pubmed: 12575899
J Hepatol. 2016 Jun;64(6):1388-402
pubmed: 27062661
World J Gastroenterol. 2019 Mar 21;25(11):1307-1326
pubmed: 30918425
Sci Rep. 2017 Aug 21;7(1):8976
pubmed: 28827690
Antioxid Redox Signal. 2018 Jul 20;29(3):275-296
pubmed: 28978222
Hepatology. 2009 Dec;50(6):1827-38
pubmed: 19937697
Medicina (Kaunas). 2020 Feb 03;56(2):
pubmed: 32028646
World J Gastroenterol. 2014 Jul 28;20(28):9330-7
pubmed: 25071327
Metabolism. 2017 May;70:177-191
pubmed: 28403941
Gastroenterology. 2016 Jun;150(8):1835-48
pubmed: 26971824
Br J Pharmacol. 1992 Oct;107(2):597-603
pubmed: 1422601
Diagnostics (Basel). 2019 Nov 27;9(4):
pubmed: 31783667
J Exp Med. 2005 Mar 7;201(5):713-22
pubmed: 15753205
Arch Iran Med. 2012 Jul;15(7):418-21
pubmed: 22724878
Nat Rev Immunol. 2015 Aug;15(8):511-23
pubmed: 26139350
FASEB J. 2009 Jun;23(6):1946-57
pubmed: 19211925
J Hepatol. 2006 Oct;45(4):600-6
pubmed: 16899321
Nat Med. 2018 Feb;24(2):213-223
pubmed: 29291351
Oncol Rep. 2016 Jan;35(1):307-17
pubmed: 26531230
Hepatology. 2007 Oct;46(4):1081-90
pubmed: 17654743
Hepatology. 2016 Jul;64(1):73-84
pubmed: 26707365
Clin Lipidol. 2013 Aug 1;8(4):411-418
pubmed: 26405460
J Leukoc Biol. 1994 Aug;56(2):200-2
pubmed: 8071595
J Lipid Res. 2010 Oct;51(10):3046-54
pubmed: 20631297
Prostaglandins Other Lipid Mediat. 2012 Oct;99(1-2):51-6
pubmed: 22706383
J Diabetes Complications. 2017 Nov;31(11):1630-1637
pubmed: 28886991
Free Radic Res. 2012 Jun;46(6):758-65
pubmed: 22468959
J Immunol. 2009 Sep 1;183(5):3383-9
pubmed: 19675173
Dig Dis Sci. 2010 Apr;55(4):931-40
pubmed: 19459046
Adv Pharmacol. 2013;66:157-266
pubmed: 23433458
J Lipid Res. 2015 Jan;56(1):185-92
pubmed: 25404585
J Immunol. 2007 Mar 15;178(6):3912-7
pubmed: 17339491
J Biol Chem. 2010 Jan 29;285(5):3451-61
pubmed: 19906641